EZM8266 是一种具有口服活性和选择性的 G9a (EHMT2) 组蛋白甲基转移酶抑制剂,对人源 EHMT2 的 IC50 为 1 pM,可降低免疫刺激基因及内源性逆转录病毒元件启动子区域的抑制性 H3K9me2 修饰标记,抑制癌细胞的集落形成、迁移及侵袭能力,增强癌细胞中的 IFN-γ 应答,提高 MHC I 类分子的表达水平,并增强 CXCL10 介导的 T 细胞募集作用,可用于肝细胞癌的相关研究。
产品编号: MS-D61474 纯度: 98.24% CAS No.: 2140164-84-5 分子式: C19H27N5O3 分子量: 373.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

EZM8266 是一种具有口服活性和选择性的 G9a (EHMT2) 组蛋白甲基转移酶抑制剂,对人源 EHMT2 的 IC50 为 1 pM,可降低免疫刺激基因及内源性逆转录病毒元件启动子区域的抑制性 H3K9me2 修饰标记,抑制癌细胞的集落形成、迁移及侵袭能力,增强癌细胞中的 IFN-γ 应答,提高 MHC I 类分子的表达水平,并增强 CXCL10 介导的 T 细胞募集作用,可用于肝细胞癌的相关研究。

生物实验数据

生物活性 EZM8266 is an orally active and selective G9a (EHMT2) histone methyltransferase inhibitor with an IC50 of 1 pM against human EHMT2, which reduces inhibitory H3K9me2 marks at promoters of immune-stimulatory genes and endogenous retroviral elements, inhibits colony formation, migration, and invasion of cancer cells, enhances IFN-γ responses in cancer cells, increases MHC class I molecule expression, and enhances CXCL10-mediated T cell recruitment, and can be used for research related to hepatocellular carcinoma.
IC50 & Target G9a:1 pM
体外研究
(In Vitro)

EZM8266 (Compound 5R) (0.5-10 μM;~15 天) 可强效抑制人 PLC/PRF/5 HCC 细胞的集落形成。
EZM8266 (0.5-10 μM;3 周) 呈剂量依赖性抑制人 PLC/PRF/5 HCC 细胞的锚定非依赖性生长。
EZM8266 (1-5 μM;72 小时) 可剂量依赖性地抑制人源 HuH7 肝癌细胞的迁移。
EZM8266 (1-5 μM;72 小时) 呈剂量依赖性抑制人源 HuH7 肝癌 (HCC) 细胞的侵袭。
EZM8266 (5 μM;48 小时) 可在人 PLC/PRF/5 肝癌 (HCC) 细胞中诱导广泛的转录重编程,上调包括固有免疫应答、干扰素信号通路和双链 RNA (dsRNA) 加工在内的免疫相关通路。
EZM8266 (5 μM;72 小时) 单独使用或与 IFN-γ 联用时,可增强小鼠 PM299L 肝癌细胞中 IFN-γ 介导的免疫相关基因 (包括趋化因子、MHC I 类组分及干扰素应答基因) 的上调表达。
EZM8266 (5 mM;72 小时) 与 IFN-γ 联用时,可协同显著提高小鼠 PM299L 和人 HuH7 肝癌细胞中 CXCL10 的分泌水平。
EZM8266 (5 mM;72 小时) 单独使用或与 IFN-γ 联合使用时,可增强 IFN-γ 介导的小鼠 PM299L 细胞和人 HuH7 肝癌 (HCC) 细胞表面 MHC I 类分子表达的上调。
EZM8266 (48 h) 可诱导小鼠和人 HCC 细胞内的双链 RNA 显著累积。

Cell Invasion Assay

Cell Line: human HuH7 HCC cells
Concentration: 1 μM; 2.5 μM; 5 μM
Incubation Time: 24 h
Result: Significantly reduced cell invasion in a dose-dependent manner, with ~60%, ~80%, and ~90% reductions at 1, 2.5, and 5 μM respectively, compared to control.

Real Time qPCR

Cell Line: murine PM299L HCC cells
Concentration: 5 μM
Incubation Time: 72 h
Result: Upregulated expression of Cxcl9, Cxcl10, B2m, Hla-a, Nlrc5, Mda5, Stat1, Rigi, Casp1, Lgals3bp, Tap1, and Irgm2 when used alone.
Produced a synergistic increase in expression of all these genes when combined with IFN-γ compared to either treatment alone.

ELISA Assay

Cell Line: murine PM299L and human HuH7 HCC cells
Concentration: 5 mM
Incubation Time: 72 h
Result: Slightly increased CXCL10 secretion when used alone, while IFN-γ alone induced a moderate increase.
Produced a synergistic, significant increase in CXCL10 secretion when combined with IFN-γ compared to either treatment alone in both PM299L and HuH7 cells.
体内研究
(In Vivo)

EZM8266 (Compound 5R) (300 mg/kg;口服;每日) 在原位小鼠肝癌模型中可显著抑制肿瘤生长,并增加瘤内 CD8+和 CD4+ T 细胞浸润。
EZM8266 (300 mg/kg;口服;每周 5 天;持续 4 周) 单药治疗可显著降低原位小鼠肝癌模型的肿瘤负荷与发病率,与抗 PD-1 联合用药则进一步增强抗肿瘤疗效、使血清肝酶水平恢复正常,并增加肿瘤内 CD8+和 CD4+ T 细胞浸润。
EZM8266 (300 mg/kg;口服;每周 5 天;持续 4 周) 单药治疗可显著降低 MYC/β-catenin 驱动的小鼠 HCC 模型中的肿瘤负荷,且与抗 PD1 联合用药可增强抗肿瘤疗效,并将肿瘤微环境重塑为免疫抑制性更低的状态。

Animal Model: C57BL/6J (male, 6-8 weeks old, orthotopic implantation of PM299L murine HCC tumor fragments)
Dosage: 300 mg/kg
Administration: p.o.; daily
Result: Significantly reduced tumor growth compared to vehicle controls.
Significantly lowered final tumor weights compared to vehicle controls.
Increased tumor-infiltrating CD8+ T cell counts to a mean of ~100 cells/mm2 (from vehicle mean ~30 cells/mm2).
Increased CD4+ T cell counts to a mean of ~100 cells/mm2 (from vehicle mean ~30 cells/mm2).
Animal Model: C57BL/6J (male, 6-8 weeks old, intrahepatic injection of PM299L murine HCC cells)
Dosage: 300 mg/kg; 300 mg/kg plus 100 μg/mouse anti-PD1
Administration: p.o.; 5 days per week; 4 weeks
Result: Reduced liver index (tumor burden) from a vehicle mean of ~18% to ~7% with monotherapy.
Reduced tumor incidence from 100% to 80% with monotherapy.
Further reduced liver index to ~3% with combination therapy.
Further reduced tumor incidence to 50% with combination therapy.
Reduced serum alanine transaminase (ALT), aspartate transaminase (AST), and lactate dehydrogenase (LDH) levels to levels comparable to age-matched normal mice.
Increased tumor-infiltrating CD8+ T cell counts to a mean of ~6000 cells/mm2 with monotherapy, and to ~8000 cells/mm2 with combination therapy (from vehicle mean ~1000 cells/mm2).
Increased CD4+ T cell counts to a mean of ~15000 cells/mm2 with combination therapy (from vehicle mean ~5000 cells/mm2).
Reduced tumor area from a vehicle mean of ~80 μm2 to ~20 μm2 with monotherapy, and to ~5 μm2 with combination therapy.
Animal Model: C57BL/6J (male, 4 weeks old, hydrodynamic tail vein injection of MYC/CTNNB1-Δ90 transposon vectors)
Dosage: 300 mg/kg; 300 mg/kg plus 100 μg/mouse anti-PD1
Administration: p.o.; 5 days per week; 4 weeks
Result: Elicited a significant antitumor response with monotherapy.
Resulted in a pronounced reduction in tumor burden with combination therapy.
Increased infiltration of CD8+ and CD4+ T lymphocytes with combination therapy.
Decreased CD4+:CD8+ ratio with combination therapy.
Reduced regulatory T cells with combination therapy.
Preserved effector memory subsets without overt T cell exhaustion with combination therapy.
性状 固体
颜色 White to off-white

化学信息

分子量 373.45
分子式 C19H27N5O3
CAS No. 2140164-84-5

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础